Immusoft has announced a significant milestone in the field of engineered B cell therapies, presenting the world’s first clinical case review of their investigational therapy ISP-001 at the FDA workshop on pediatric cell and gene therapy. This case review will detail the initial clinical experiences of the first patient treated with ISP-001 for mucopolysaccharidosis type I (MPS I), a severe genetic disorder. Early results from the ongoing Phase 1/2 trial indicate a favorable safety profile, including successful re-dosing of the first patient, who continues to show promising pharmacodynamic and quality-of-life improvements.

The implications of these findings are substantial. ISP-001 utilizes the patient’s own B cells as “living biofactories” to produce the deficient enzyme α-L-iduronidase (IDUA), addressing the underlying cause of MPS I. This approach not only aims to provide sustained therapeutic protein expression but also seeks to mitigate the limitations of existing therapies, such as the “sawtooth effect” seen with enzyme replacement therapies and the risks associated with stem cell transplants. The ongoing trial is bolstered by $23 million in funding from the California Institute for Regenerative Medicine, underscoring the potential impact of this innovative therapy.

The successful administration of ISP-001 marks a pivotal shift in the landscape of cell and gene therapies. As the first engineered B cell therapy to show clinical efficacy, it may redefine treatment paradigms for rare genetic disorders, potentially accelerating timelines for drug development in similar therapeutic areas. This case not only highlights the therapeutic potential of reprogrammed B cells but also sets a precedent for future research into engineered cell therapies aimed at rare and complex diseases.

Source: globenewswire.com